|Bid||5.40 x 900|
|Ask||5.93 x 800|
|Day's Range||5.62 - 5.93|
|52 Week Range||3.25 - 17.40|
|Beta (3Y Monthly)||-0.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.05|
AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Lausanne, Switzerland-based company said it had net income of 91 cents per share. Earnings, adjusted for non-recurring gains, came to 85 cents per share. The biopharmaceutical company posted revenue ...
LAUSANNE, Switzerland, May 15, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering.
"Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls AC Immune SA (NASDAQ:ACIU), then you'll have to look at the makeup of its share regis...
LAUSANNE, Switzerland, April 01, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
Demonstrated high-affinity binding to human Parkinson’s disease-brain derived alpha-synucleinPotentially first diagnostic for detecting and monitoring Parkinson’s diseaseFurther.
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP New data further support 18F-PI-2620’s potential as.
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates MorphomerTM platform Initiation of second Phase 2 trial of Tau antibody.
LAUSANNE, Switzerland, March 04, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
Study complements ongoing trial in the prodromal to mild population LAUSANNE, Switzerland, Feb. 20, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage.
LAUSANNE, Switzerland, Feb. 07, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
Why Did AC Immune SA Stock Crash on January 30?Share price movementsOn January 30, AC Immune SA (ACIU) issued a press release announcing the discontinuation of Phase 3 trials, CREAD 1 and CREAD 2, by Roche Holdings (RHHBY). The decision was based on
Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Biogen stock slipped Wednesday after Roche and AC Immune opted to scrap two Alzheimer's treatment studies — leading investors to look for details of Biogen's own experimental drug.
Roche Holding and partner AC Immune SA called a halt to two late-stage clinical trials of their crenezumab drug for early Alzheimer's, the latest in a string of failures to find a treatment for the progressive brain disease. The announcement from Roche and its Swiss-based partner AC Immune came after an interim analysis indicated it was unlikely to be effective, the Swiss drugmaker said on Wednesday. Alzheimer's, a fatal disease which affects memory and language as it progresses, is a compelling target for drugmakers as the numbers affected across the globe swell with an ageing population, but experimental Alzheimer's drugs have had a dismal track record, with more than 100 failures.